ZA201800939B - Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same - Google Patents

Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same

Info

Publication number
ZA201800939B
ZA201800939B ZA2018/00939A ZA201800939A ZA201800939B ZA 201800939 B ZA201800939 B ZA 201800939B ZA 2018/00939 A ZA2018/00939 A ZA 2018/00939A ZA 201800939 A ZA201800939 A ZA 201800939A ZA 201800939 B ZA201800939 B ZA 201800939B
Authority
ZA
South Africa
Prior art keywords
delivery
methods
same
genetically encoded
intrinsically disordered
Prior art date
Application number
ZA2018/00939A
Other languages
English (en)
Inventor
Chilkoti Ashutosh
Banskota Samagya
YOUSEFPOUR Parisa
Bhattacharyya Jayanta
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of ZA201800939B publication Critical patent/ZA201800939B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
ZA2018/00939A 2015-08-04 2018-02-12 Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same ZA201800939B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562200726P 2015-08-04 2015-08-04
PCT/US2016/045655 WO2017024182A1 (en) 2015-08-04 2016-08-04 Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same

Publications (1)

Publication Number Publication Date
ZA201800939B true ZA201800939B (en) 2019-05-29

Family

ID=57943998

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/00939A ZA201800939B (en) 2015-08-04 2018-02-12 Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same

Country Status (12)

Country Link
US (1) US11458205B2 (cg-RX-API-DMAC7.html)
EP (1) EP3331557B1 (cg-RX-API-DMAC7.html)
JP (1) JP6882782B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180033586A (cg-RX-API-DMAC7.html)
CN (1) CN108463244B (cg-RX-API-DMAC7.html)
AU (1) AU2016301391B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018002342A2 (cg-RX-API-DMAC7.html)
CA (1) CA2994279A1 (cg-RX-API-DMAC7.html)
EA (1) EA037478B1 (cg-RX-API-DMAC7.html)
MX (1) MX2018001511A (cg-RX-API-DMAC7.html)
WO (1) WO2017024182A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201800939B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
EP3331557B1 (en) 2015-08-04 2021-04-07 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
CN109890833A (zh) 2016-09-14 2019-06-14 杜克大学 用于递送亲水性药物的基于三嵌段多肽的纳米粒子
KR20190064600A (ko) 2016-09-23 2019-06-10 듀크 유니버시티 Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
EP3658168A4 (en) 2017-06-30 2021-07-14 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULUS SENSITIVE BIOPOLYMER NETWORKS
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
US12257308B2 (en) 2018-04-30 2025-03-25 Duke University Stimuli-responsive PEG-like polymer-based drug delivery platform
EP3829622A4 (en) 2018-08-02 2022-05-11 Duke University DOUBLE AGONIST FUSION PROTEINS
JP2022512661A (ja) * 2018-10-10 2022-02-07 ユニヴァーシティ オブ ワシントン 混合荷電ペプチドを含む融合生成物およびバイオコンジュゲート
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
JP2022551931A (ja) * 2019-10-11 2022-12-14 ユニヴァーシティ オブ ワシントン 改変エンドヌクレアーゼおよび関連方法
WO2021252391A1 (en) * 2020-06-09 2021-12-16 Academia Sinica Methods and vectors for enhancing expression and/or inhibiting degradation of protein

Family Cites Families (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4976734A (en) 1985-10-31 1990-12-11 Uab Research Foundation Stimulation of chemotaxis by chemotactic peptides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5250516A (en) 1986-04-17 1993-10-05 Uab Research Foundation Bioelastomeric materials suitable for the protection of burn areas or the protection of wound repair sites from the occurrence of adhesions
US5336256A (en) 1986-04-17 1994-08-09 Uab Research Foundation Elastomeric polypeptides as vascular prosthetic materials
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5602244A (en) 1988-05-26 1997-02-11 Competitive Technologies, Inc. Polynucleotide phosphorodithioate compounds
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5362623A (en) 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
DE69128350T2 (de) 1990-06-11 1998-03-26 Nexstar Pharmaceuticals Inc Nukleinsäureliganden
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
US5534408A (en) 1993-09-24 1996-07-09 University Of Massachusetts Medical Center 2-deoxystreptamine aminoglycoside inhibition of HIV RRE/Rev binding
EP0668766A1 (en) 1992-10-23 1995-08-30 University Of Massachusetts Medical Center Small molecule inhibition of rna/ligand binding
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US6933366B2 (en) 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US5763548A (en) 1995-03-31 1998-06-09 Carnegie-Mellon University (Co)polymers and a novel polymerization process based on atom (or group) transfer radical polymerization
US6541580B1 (en) 1995-03-31 2003-04-01 Carnegie Mellon University Atom or group transfer radical polymerization
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
AU740207B2 (en) 1997-02-06 2001-11-01 Novozymes A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
US6974669B2 (en) 2000-03-28 2005-12-13 Nanosphere, Inc. Bio-barcodes based on oligonucleotide-modified nanoparticles
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
US7087244B2 (en) 2000-09-28 2006-08-08 Battelle Memorial Institute Thermogelling oligopeptide polymers
US6296831B1 (en) 1998-04-10 2001-10-02 Battelle Memorial Institute Stimulus sensitive gel with radioisotope and methods of making
US6841617B2 (en) 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
ATE275977T1 (de) 1998-04-13 2004-10-15 Massachusetts Inst Technology Kamm-polymere zur regelung der zelloberflächenwechselwirkung
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
AU761522B2 (en) 1998-07-13 2003-06-05 Genetronics, Inc. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
US6413587B1 (en) 1999-03-02 2002-07-02 International Business Machines Corporation Method for forming polymer brush pattern on a substrate surface
AU3867400A (en) 1999-03-19 2000-10-09 Duke University Methods of using bioelastomers
US7163712B2 (en) 2000-03-03 2007-01-16 Duke University Microstamping activated polymer surfaces
US6852834B2 (en) 2000-03-20 2005-02-08 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
US20050255554A1 (en) 2000-03-20 2005-11-17 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
US7351376B1 (en) 2000-06-05 2008-04-01 California Institute Of Technology Integrated active flux microfluidic devices and methods
US6660247B1 (en) 2000-06-23 2003-12-09 Battelle Memorial Institute Multiple stimulus reversible hydrogels
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
EP1455816A4 (en) 2000-10-19 2007-03-28 Epimmune Inc HLA CLASS I AND II BINDING PEPTIDES AND THEIR USE
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US6528287B2 (en) 2001-02-13 2003-03-04 Nestor D. Tomycz Recombinant human serum transferrins containing peptides for inducing apoptosis in HIV-1 infected cells
AU2002307151A1 (en) 2001-04-06 2002-10-21 Carnegie Mellon University A process for the preparation of nanostructured materials
US6960437B2 (en) 2001-04-06 2005-11-01 California Institute Of Technology Nucleic acid amplification utilizing microfluidic devices
EP2364990A1 (en) 2001-05-25 2011-09-14 Duke University Modulators of pharmacological agents
US20070117173A1 (en) 2001-09-05 2007-05-24 Levison Peter R Stable storage of proteins
AU2002365396A1 (en) 2001-11-21 2003-06-10 The Trustees Of The University Of Pennsylvania Peptides, peptide compositions,and methods of use in binding p 185
WO2003048295A1 (en) 2001-11-30 2003-06-12 Fluidigm Corporation Microfluidic device and methods of using same
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US20040101852A1 (en) 2002-11-21 2004-05-27 Isis Pharmaceuticals Inc. Modulation of CGG triplet repeat binding protein 1 expression
CN1649899A (zh) 2002-05-03 2005-08-03 米列姆·贝尔罗吉克公司 结缔组织刺激肽
CA2525994C (en) 2002-06-24 2012-10-16 Tufts University Silk biomaterials and methods of use thereof
EP1534340B1 (en) 2002-09-06 2011-11-16 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US6918284B2 (en) 2003-03-24 2005-07-19 The United States Of America As Represented By The Secretary Of The Navy Interconnected networks of single-walled carbon nanotubes
WO2004096124A2 (en) 2003-04-01 2004-11-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP5019511B2 (ja) 2003-09-17 2012-09-05 サイトリ セラピューティクス インコーポレイテッド 抹消血管疾患およびそれに関連する障害の治療において新生細胞を利用する方法
US7335744B2 (en) 2003-12-23 2008-02-26 The Regents Of The California University Prostate cancer specific internalizing human antibodies
AU2005238490B2 (en) 2004-04-22 2010-11-18 Tobira Therapeutics, Inc. Improved modulators of coagulation factors
WO2006004778A2 (en) 2004-06-30 2006-01-12 Dentsply International Inc. Implant with a biofunctionalized surface and method for its production
US7884185B2 (en) 2004-07-28 2011-02-08 University Of Delaware Hydrogels and uses thereof
WO2006020719A2 (en) 2004-08-11 2006-02-23 Arqule, Inc. Aminoacid conjugates of beta - lapachone for tumor targeting
WO2006110292A2 (en) 2005-03-25 2006-10-19 The Regents Of The University Of California Temperature-triggered immobilization and purification of antibodies
KR101637140B1 (ko) 2005-05-09 2016-07-06 테라노스, 인코포레이티드 현장진료 유체 시스템 및 그 용도
WO2007002362A2 (en) * 2005-06-24 2007-01-04 Duke University A direct drug delivery system based on thermally responsive biopolymers
JP6085075B2 (ja) 2005-08-25 2017-02-22 ユニヴァーシティ オブ ワシントン 超低汚損スルホベタインおよびカルボキシベタイン材料ならびに関連する方法
WO2007035527A2 (en) 2005-09-15 2007-03-29 Duke University Non-fouling polymeric surface modification and signal amplification method for biomolecular detection
WO2008002462A2 (en) 2006-06-23 2008-01-03 Micronics, Inc. Methods and devices for microfluidic point-of-care immunoassays
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8178495B2 (en) 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
US8334257B2 (en) 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US7709227B2 (en) 2006-01-04 2010-05-04 Phasebio Pharmaceuticals, Inc. Multimeric ELP fusion constructs
US8841414B1 (en) 2006-01-27 2014-09-23 University Of Mississippi Medical Center Targeted delivery of therapeutic peptides by thermally responsive biopolymers
WO2007108013A2 (en) 2006-03-22 2007-09-27 National Institute Of Immunology Novel bioconjugates as therapeutic agent and synthesis thereof
WO2007134245A2 (en) * 2006-05-12 2007-11-22 Wisconsin Alumni Research Foundation Elastin-like polymer delivery vehicles
PT2402369E (pt) 2006-06-13 2016-02-19 Helix Biomedix Inc Fragmentos peptídicos para induzir a síntese de proteínas da matriz extracelular
DE602006018206D1 (de) 2006-06-23 2010-12-23 St Microelectronics Srl Anordnung einer mikrofluidvorrichtung zur analyse von biologischem material
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
US20110039776A1 (en) 2006-09-06 2011-02-17 Ashutosh Chilkoti Fusion peptide therapeutic compositions
US8846624B2 (en) 2006-09-11 2014-09-30 Emory University Modified protein polymers
WO2008043041A1 (en) 2006-10-04 2008-04-10 University Of Washington Method and device for rapid parallel microfluidic molecular affinity assays
WO2008055931A1 (de) 2006-11-08 2008-05-15 Basf Se Verwendung von natürlichen, rekombinanten und synthetischen resilinen in der kosmetik
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
CN101702917A (zh) 2007-03-30 2010-05-05 杜克大学 一种调节核酸分子活性的方法
ES2346178T3 (es) 2007-07-31 2015-11-02 Affibody Ab Nuevas composiciones, procedimientos y usos de unión de la albúmina
US20090098652A1 (en) 2007-08-17 2009-04-16 Northwestern University Self assembling peptide systems and methods
US8366652B2 (en) 2007-08-17 2013-02-05 The Invention Science Fund I, Llc Systems, devices, and methods including infection-fighting and monitoring shunts
ES2319061B1 (es) 2007-09-11 2010-02-10 Biomedal, S.L. Metodo de conservacion de peptidos o proteinas.
CA2934220C (en) 2007-10-02 2019-11-05 Theranos, Inc. Modular point-of-care devices and uses thereof
WO2009067584A1 (en) 2007-11-20 2009-05-28 Duke University Methods and compositions for modulating drug-polymer architecture, pharmacokinetics and biodistribution
DE102007057802B3 (de) * 2007-11-30 2009-06-10 Geneart Ag Steganographische Einbettung von Informationen in kodierenden Genen
BRPI0820738A2 (pt) 2007-12-14 2015-06-16 Minitube America Inc Separação específica do gênero de células de esperma e embriões
US8796184B2 (en) 2008-03-28 2014-08-05 Sentilus, Inc. Detection assay devices and methods of making and using the same
KR101026468B1 (ko) 2008-09-10 2011-04-01 한국전자통신연구원 생분자 검출 장치 및 검출 방법
CN102231951A (zh) 2008-11-17 2011-11-02 安龙制药公司 用于核酸传递系统的可释放的偶联物
WO2010054699A1 (en) 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
EP3059247B1 (en) 2008-12-05 2017-09-20 Abraxis BioScience, LLC Sparc binding peptides and uses thereof
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
WO2010096422A1 (en) 2009-02-17 2010-08-26 Duke University Biomolecule polymer conjugates and methods for making the same
US8586347B2 (en) 2010-09-15 2013-11-19 Mbio Diagnostics, Inc. System and method for detecting multiple molecules in one assay
EP2440235A1 (en) 2009-06-11 2012-04-18 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
USPP21973P3 (en) 2009-06-23 2011-06-14 Cellfor Inc. Loblolly pine tree named ‘CF LP1-7696’
EP2287221A1 (en) 2009-07-16 2011-02-23 Stichting Katholieke Universiteit meer in het bijzonder Radboud Universiteit Nijmegen Method for the preparation of high molecular weight oligo(alkylene glycol) functionalized polyisocyanopeptides
CA2772551A1 (en) * 2009-08-26 2011-03-03 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2011035465A1 (zh) 2009-09-22 2011-03-31 上海市肿瘤研究所 特异性结合蛋白及其使用
US8602051B2 (en) 2009-12-10 2013-12-10 Brent W. Proper Trap-primer system for floor drains
WO2011100700A2 (en) 2010-02-12 2011-08-18 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
EP2550529B1 (en) 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
US8557961B2 (en) 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
JP2011220803A (ja) 2010-04-08 2011-11-04 Mitsumi Electric Co Ltd 電界効果トランジスタ素子を具備するバイオセンサ
ES2755398T3 (es) 2010-04-13 2020-04-22 Medimmune Llc Andamios multiméricos específicos de TRAIL R2
CN103108587B (zh) 2010-05-17 2016-09-21 申提留斯控股有限公司 检测装置和相关使用方法
EP2418284A1 (en) 2010-08-13 2012-02-15 ERA Biotech, S.A. Protein body-inducing polypeptide sequences
US9090869B2 (en) 2010-06-10 2015-07-28 Kyushu Institute Of Technology Temperature responsive sheet that displays reversible properties and cell sheet production method using same
US8470967B2 (en) 2010-09-24 2013-06-25 Duke University Phase transition biopolymers and methods of use
US8680045B2 (en) 2010-11-01 2014-03-25 Peptimed, Inc. Compositions of a peptide targeting system for treating cancer
WO2012162426A1 (en) 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for heptameric targeting ligands
KR101357117B1 (ko) 2011-06-28 2014-02-06 비앤엘델리팜 주식회사 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
US9775803B2 (en) 2011-10-19 2017-10-03 Samsung Electronics Co., Ltd. Liposome comprising elastin-like polypeptide and tumor cell targeting material and use thereof
WO2013059805A1 (en) 2011-10-21 2013-04-25 Decimadx, Llc Point-of care immunoassay for quantitative small analyte detection
WO2013065009A1 (en) 2011-11-01 2013-05-10 National Institute Of Immunology A sortase-click reaction suite for synthesis of multivalent dendrimeric protein assembly
RU2014126244A (ru) 2011-11-28 2016-01-27 Фэйзбио Фармасьютикалз, Инк. Лекарственные средства, содержащие аминокислотные последовательности инсулина
EP2802308A1 (en) 2012-01-13 2014-11-19 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
CN103239423A (zh) 2012-02-01 2013-08-14 三星电子株式会社 固体脂质纳米粒、含其的药物组合物、及其用途
EP2892919A1 (en) 2012-09-07 2015-07-15 Sanofi Fusion proteins for treating a metabolic syndrome
US9828415B2 (en) 2013-01-30 2017-11-28 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
JP2014156428A (ja) 2013-02-15 2014-08-28 Univ Of Tokyo 抗体結合タンパク質
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
KR102109188B1 (ko) 2013-04-01 2020-05-11 삼성전자주식회사 양이온성 지질을 포함하는 온도민감성 리포좀 및 그의 용도
WO2014194244A1 (en) 2013-05-30 2014-12-04 Duke University Enzyme-catalyzed synthesis of site-specific and stoichiometric biomolecule-polymer conjugates
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
WO2015011231A1 (en) 2013-07-25 2015-01-29 Universitat Rovira I Virgili Method and system for the multiplex identification of analytes in fluids
US9777041B2 (en) 2013-09-09 2017-10-03 New York University Protein nanofibers from self-assembling pentamers
JP6584012B2 (ja) 2013-10-06 2019-10-02 アメリカ合衆国 改変シュードモナス外毒素ａ
AU2014342004B2 (en) 2013-11-01 2017-10-26 Yale University Modular particles for immunotherapy
WO2015126480A2 (en) 2013-11-13 2015-08-27 Massachusetts Institute Of Technology Self-assembling underwater adhesives
WO2015120091A1 (en) 2014-02-04 2015-08-13 Duke University Systems and devices for protease detection based on engineered polymers and biopolymers and methods of use
WO2015120287A2 (en) 2014-02-06 2015-08-13 Yale University Compositions and methods of use thereof for making polypeptides with many instances of nonstandard amino acids
WO2015130846A2 (en) 2014-02-25 2015-09-03 Duke University Compositions and methods for the site-specific modification of polypeptides
US10131690B2 (en) 2014-04-25 2018-11-20 Phi Pharma Sa C6S specific transporter molecules
BR102014014502B1 (pt) 2014-06-13 2020-09-15 Ouro Fino Saúde Animal Ltda Vetor de expressão
CN104725628B (zh) 2014-10-01 2018-04-17 厦门赛诺邦格生物科技股份有限公司 一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质
CN104877127B (zh) 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
WO2016065273A1 (en) 2014-10-24 2016-04-28 The University Of Chicago Heat-inducible self-assembling protein domains
WO2016065300A1 (en) 2014-10-24 2016-04-28 Eshoo Mark W Microfluidic cartridge
EP3227348A4 (en) 2014-12-04 2018-07-18 The Trustees of Columbia University in the City of New York Biodegradable thermo-responsive polymers and uses thereof
US9702847B2 (en) 2014-12-30 2017-07-11 Avails Medical, Inc. Systems and methods for detecting a substance in bodily fluid
US9804170B2 (en) 2015-02-09 2017-10-31 Bristol-Myers Squibb Company Antibodies to polyethylene glycol
US9956300B2 (en) 2015-03-18 2018-05-01 Duke Univerity Hydrogels formed from polypeptide micelles and methods of use thereof
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
US10064954B2 (en) 2015-06-23 2018-09-04 Nian Wu Polymer-cyclodextrin-lipid conjugates
AU2016287499B2 (en) 2015-06-29 2022-08-04 Caris Science, Inc. Therapeutic oligonucleotides
CA2993002A1 (en) 2015-07-20 2017-01-26 Sentilus Holdco, Llc Chips, detectors, and methods of making and using the same
EP3331557B1 (en) 2015-08-04 2021-04-07 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
WO2017027384A1 (en) 2015-08-07 2017-02-16 Poc Medical Systems, Inc. Microfluidic devices and methods of use thereof
US9678037B2 (en) 2015-10-08 2017-06-13 The Regents Of The University Of Michigan Two-dimensional material-based field-effect transistor sensors
CA3040110A1 (en) 2015-10-13 2017-04-20 Daniel C. Carter Nsp10 self-assembling fusion proteins for vaccines, therapeutics, diagnostics and other nanomaterial applications
SMT202300052T1 (it) 2015-10-28 2023-05-12 Acuitas Therapeutics Inc Nuovi lipidi e for­mulazioni di nanoparticelle lipidiche per il rilascio di acidi nucleici
US10633662B2 (en) 2015-11-10 2020-04-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating AAV infection
US9496239B1 (en) 2015-12-11 2016-11-15 International Business Machines Corporation Nitride-enriched oxide-to-oxide 3D wafer bonding
WO2017112826A2 (en) 2015-12-21 2017-06-29 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
CA3019325A1 (en) 2016-03-31 2017-10-05 Ajinomoto Co., Inc. Fibroin-like protein variant and cell culture method
EP4043010A1 (en) 2016-05-06 2022-08-17 Phasebio Pharmaceuticals, Inc. Elp fusion proteins for controlled and sustained release
US20200163878A1 (en) 2016-10-26 2020-05-28 Curevac Ag Lipid nanoparticle mrna vaccines
MX2019007584A (es) 2016-12-22 2019-09-04 Sanofi Sa Combinaciones de compuesto de fgf21/agonista de glp-1r con una proporcion de actividades optimizada.
WO2018126084A1 (en) 2016-12-30 2018-07-05 Phaserx, Inc. Branched peg molecules and related compositions and methods
WO2018144854A1 (en) 2017-02-02 2018-08-09 Caris Science, Inc. Targeted oligonucleotides
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
AU2018283184B2 (en) 2017-06-14 2021-08-19 EMULATE, Inc. Effects of space travel on human brain cells
EP3658168A4 (en) 2017-06-30 2021-07-14 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULUS SENSITIVE BIOPOLYMER NETWORKS
US11235324B2 (en) 2017-11-22 2022-02-01 Hewlett-Packard Development Company, L.P. Temperature-cycling microfluidic devices
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
US20190292549A1 (en) 2018-03-22 2019-09-26 Northeastern University Poly(ethylene glycol) brushes for efficient rna delivery
EP4458351A3 (en) 2018-08-17 2025-05-21 The Regents of the University of California Particle-containing droplet systems with monodisperse fluid volumes
US20220146502A1 (en) 2019-02-01 2022-05-12 Sentilus Holdco, Llc High-sensitivity assay

Also Published As

Publication number Publication date
MX2018001511A (es) 2018-08-01
US20180228908A1 (en) 2018-08-16
WO2017024182A1 (en) 2017-02-09
EP3331557A1 (en) 2018-06-13
CN108463244B (zh) 2022-05-27
EP3331557B1 (en) 2021-04-07
AU2016301391A1 (en) 2018-02-22
CN108463244A (zh) 2018-08-28
KR20180033586A (ko) 2018-04-03
US11458205B2 (en) 2022-10-04
EA201890417A1 (ru) 2018-08-31
EP3331557A4 (en) 2019-03-13
AU2016301391B2 (en) 2022-07-28
BR112018002342A2 (pt) 2018-12-11
JP6882782B2 (ja) 2021-06-02
EA037478B1 (ru) 2021-04-01
JP2018525989A (ja) 2018-09-13
CA2994279A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
ZA201800939B (en) Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
IL287605A (en) Injectable delivery devices, systems and methods
ZA201703639B (en) Self-orienting syringe and syringe interface
ZA201703640B (en) Self-orienting syringe and syringe interface
ES3050007T3 (en) Oligomers and oligomer conjugates
EP3785753C0 (en) DEVICES FOR DELIVERING HEMOSTATIC POWDER
PL3159367T3 (pl) Kompozycja żywicy kopoliwęglanowej i obejmujący ją wyrób
HUE055460T2 (hu) Készítmények és módszerek a célzott citokin bejuttatására
GB201807588D0 (en) Targeted location product delivery systems and methods
GB201503393D0 (en) Polymers and uses thereof
ZA201800130B (en) Improved nanoparticle delivery systems
PL3274411T3 (pl) Trwałe polimery zapobiegające powstawaniu odcisków palców i kompozycje powlekające
IL262310A (en) Advanced methods of gene insertion
PL3328361T3 (pl) Cząstki nanożywicy zawierające lek
GB201515602D0 (en) Polymers and microspheres
IL250844A0 (en) Medical nanoparticles and related preparations, methods and systems
GB201402783D0 (en) Powder delivery means
GB201510461D0 (en) New polymers and methods
IL248863A0 (en) Preparations containing il-31 and their use
GB201510460D0 (en) New polymers and methods
GB201503996D0 (en) Storage and delivery assembly